Letsbeclear wrote: Here's my analysis of THCBiomed during the time period of January 2019 - January 2020:
Recreational
1) Production capacity : 20000kg [?]
2) Goods sold : 2,390,200g + Ontario 1,000,000g [dried & oil based sales]
3) Sale price: $4/g [averaged between dried flower and higher margined oils]
4) Revenue : $13,560,800
Medical
1) Goods sold: 1000kg [dries & oil based sales]
2) Sale price per g: $6.50 [averaged between dried flower and higher margined extracts]
3) Revenue: $6,500,000
Total Revenue: $20,060,800
1) Cost of production (All-in cost): $1.50/g
2) Cost of production (total) : 6.585M
3) Other costs : +or- 7M
4) Total of costs : $13,585,000
Net Profit : $6,475,800
Number of Shares Ending January 2019 : 125 M (Currently at 118.27 M * Aug 20, 2018 but let's not neglect the high likelihood for further strategic dilution, which I support, to acquire valuable assets that will strengthen THCs portfolio of brands and research and developments (e.g. cannabis infused drinks and necessary patents for such a step in the cannabis sector along with standardized and accurate dosage labelling for retail marijuana consumption.
Earnings per share : January 2020 = $0.052 (May 31, 2018 -.06 EPS = 187% increase)
Valuation Multiple:
0.052 * 40 = $2.08 SP
0.052 * 25 = $1.30SP
Would ANY bashers like to tell me I am wrong? THC long!